India, a nation aspiring to cement its position as a global pharmaceutical and biotechnology powerhouse, confronts a foundational challenge in its ambition: a notable deficit in standardized, trial-ready healthcare facilities capable of meeting the burgeoning demands of international clinical research. This infrastructural bottleneck, characterized by unevenly equipped sites concentrated primarily in major urban centers and hampered by inconsistent operational protocols, threatens to impede the country’s ascent in the high-stakes world of drug development. To address this critical lacuna, the Indian government has unveiled a transformative initiative, the Biopharma Shakti scheme, a strategic plan to establish a national network of over 1,000 accredited clinical trial sites, announced as part of a recent Union Budget proposal and slated for significant scale-up by the fiscal year 2026-27. This ambitious undertaking is designed to streamline the research landscape, attract greater foreign investment, and solidify India’s role as an indispensable hub for medical innovation.
The global pharmaceutical industry invests staggering sums in research and development, with clinical trials representing the most significant portion of this expenditure, often accounting for 60-70% of the total R&D budget for a new drug. As pharmaceutical companies worldwide grapple with escalating costs and the imperative to accelerate drug discovery, the search for efficient, cost-effective, and diverse patient populations for clinical validation intensifies. India presents a compelling proposition in this global calculus. Its immense and genetically diverse population, coupled with a rising incidence of non-communicable diseases such as diabetes, cardiovascular ailments, and various cancers—conditions that align with major therapeutic areas in global pipelines—offers an unparalleled patient pool. Furthermore, the operational costs associated with conducting clinical trials in India are significantly lower, often estimated to be 50-60% less than in Western nations, primarily due to reduced personnel expenses and lower overheads. This potent combination of demographic advantage and economic viability positions India as an attractive destination for global sponsors.
Beyond the immediate cost efficiencies, India’s strategic pivot towards becoming a biopharma hub is another powerful catalyst. The "Make in India" initiative extends to pharmaceuticals, aiming not just for manufacturing prowess but also for leadership in research and development. A crucial component of this vision is the burgeoning biosimilars market, where India already holds a strong global position. Unlike generic drugs, which primarily require bioequivalence studies, biosimilars necessitate comprehensive human trials to establish their safety and efficacy against innovator biologics, thereby driving an inherent demand for robust clinical trial infrastructure. While India’s historical contribution to global clinical trials remained relatively modest, regulatory reforms implemented since 2014 have spurred remarkable growth. A 2023 PwC report indicated a 40% increase in clinical trial sites between 2014 and 2022. More impressively, India’s share in global clinical trials surged from approximately 4% between 2012 and 2022 to an estimated 9.38% as of June 2025, according to World Health Organization data, placing it as the third-largest country for clinical trials after the United States and China. Notably, India stands out as one of the few nations that did not experience a decline in trial activity following the peak of the COVID-19 pandemic, underscoring its growing resilience and attractiveness.
Currently, clinical trials in India are typically managed by pharmaceutical companies directly or, more commonly, outsourced to Contract Research Organizations (CROs). These entities operate under the stringent oversight of the central drug regulatory authority, identifying and collaborating with medical institutions, hospitals, or large clinics to execute studies. All clinical trials in India must be meticulously registered with the Clinical Trials Registry – India (CTRI), a mandate in place since 2009, with over 102,825 trials registered to date. Each trial site is also required to register its Ethics Committee with the Drugs Controller General of India (DCGI), ensuring adherence to ethical guidelines. The upward trajectory in demand is evident: trials sponsored by the top 20 global pharmaceutical companies in India witnessed a 10% increase between 2013 and 2022, with industry giants like AstraZeneca, Novartis, Eli Lilly, Pfizer, and Johnson & Johnson leading the sponsorship. Projections from a 2023 study by the Department of Pharmaceuticals (DoP) forecast the Indian CRO sector to expand at a Compound Annual Growth Rate (CAGR) of 10.75%, reaching a market value of $2.5 billion by 2030. This growth is intrinsically linked to the broader global pharmaceutical R&D outsourcing market, projected to hit $90.4 billion by 2030, with clinical development outsourcing accounting for a substantial $61.2 billion, or 67% of this total.
The proposed accreditation network, therefore, represents a pivotal intervention. Industry experts and medical professionals emphasize that such a system could significantly lower entry barriers for a multitude of hospitals and clinics that presently lack the requisite internal systems and infrastructure to host trials. For a facility to effectively serve as a clinical trial site, it demands not just basic medical infrastructure but also specialized equipment, robust data management systems, and a cadre of trained personnel, elements often concentrated in tier-1 metropolitan healthcare institutions. As Saurabh Arora, managing director of Auriga Research, a Delhi-based CRO, notes, "Bringing in these accredited sites will definitely accelerate the process of being able to start the trials because they will have certain processes and capabilities already established." Dr. Ashish Joshi, an oncologist and co-founder of M|O|C Cancer Care & Research Centre, highlights the potential for democratizing research, allowing it to move beyond the confines of a select few elite institutions. This standardization provides a clear framework for infrastructure, personnel, and ethical processes, reducing the wide variations currently observed in study conduct and offering clearer expectations for both sponsors and regulators. From a regulatory perspective, operating against common benchmarks enables more effective and uniform oversight, enhancing data quality and patient safety.
However, the efficacy of the Biopharma Shakti scheme extends beyond mere physical infrastructure. The most significant roadblock to India’s clinical trial ambitions lies in the critical shortage of trained clinicians, research nurses, study coordinators, and support staff. While facilities can be built, the human capital required to run complex, ethically sound trials to global standards is paramount. The successful implementation of 1,000+ accredited sites will necessitate a parallel, massive investment in skill development and capacity building across the healthcare ecosystem. Sanjay Vyas, president and managing director of Paraxel India, a global CRO, underscores this, stating, "What is required is to provide the necessary clinical trial-specific training and processes to the site personnel so that the clinical trials we run meet the highest standards of patient care and data quality." This includes rigorous training in Good Clinical Practice (GCP), regulatory compliance, data integrity, and patient management specific to research protocols.
Another enduring challenge, despite recent improvements, remains the regulatory landscape. While amendments since 2013 have commendably streamlined approval processes, reducing timelines by an estimated 30-40%, delays can still be a deterrent for international drugmakers accustomed to faster turnaround times in other emerging markets. The DoP report acknowledges that these delays have significantly impacted the CRO industry. A contributing factor is the persistent shortage of scientific and technical experts within the Central Drugs Standard Control Organisation (CDSCO), India’s primary drug regulatory body, and within various ethics committees. The Biopharma Shakti scheme directly addresses this by announcing the creation of a dedicated cadre of scientific and technical experts for the CDSCO. This initiative is crucial for enhancing regulatory efficiency, ensuring timely and informed reviews, and fostering greater consistency in decision-making, thereby instilling confidence among global sponsors. Furthermore, robust and independent ethics committees, equipped with trained personnel and standardized review processes, are fundamental to upholding patient safety and ethical research practices, which are non-negotiable for international credibility.
The successful realization of the Biopharma Shakti scheme holds immense economic promise for India. By establishing a world-class network of clinical trial sites, the nation can significantly increase its share of the global clinical research market, attracting substantial foreign direct investment from pharmaceutical companies and CROs. This influx of investment will not only create numerous high-skilled job opportunities across medical, scientific, and administrative domains but also facilitate invaluable knowledge transfer and technological advancements. Moreover, by fostering a more robust and predictable clinical research environment, India can move beyond being solely a destination for outsourced trials to nurturing its own indigenous drug discovery and development ecosystem. This strategic move could transform India from a pharmaceutical manufacturing hub into a genuine innovation hub, driving self-reliance in healthcare solutions and enhancing its global competitiveness. While the road ahead will demand sustained investment, meticulous coordination across various stakeholders, continuous skill upgradation, and unwavering commitment to ethical standards, the Biopharma Shakti initiative represents a monumental step towards unlocking India’s full potential in global clinical research and solidifying its position as a leader in biomedical innovation.
